‘MAHA Report’ Calls for Fighting Chronic Disease, but Trump and Kennedy Have Yanked Funding

The Trump administration has declared that it will aggressively combat chronic disease in America. Yet in its feverish purge of federal health programs, it has proposed eliminating the National Center for Chronic Disease Prevention and Health Promotion and its annual funding of $1.4 billion. That’s one of many disconnects between what the administration says about…

Read More

Cost-effectiveness analysis model for sotagliflozin compared with insulin monotherapy for patients with type 1 diabetes and chronic kidney disease

That is the title of my latest paper in JMCP with co-authors Jaehong Kim, Shanshan Wang, Moises Marin, Slaven Sikirica, and Mariam Anderson. The study abstract is below. BACKGROUND: Patients with type 1 diabetes (T1D) have a greater than 50% lifetime risk of developing comorbid chronic kidney disease (CKD). Glycemic control can reduce diabetes-related complications…

Read More

We’ve Never Seen Health Care Cuts This Big

In this July 1 column for The New York Times Opinion section, KFF Executive Vice President for Health Policy Larry Levitt explains how the budget reconciliation bill passed by the Senate on July 1 is effectively a partial repeal of the Affordable Care Act (ACA) and, if signed into law, the resulting reductions in Medicaid…More

Read More

MIT Spinout Syntis Bio Secures $38M for a Novel Approach to Treating Obesity and More

Instead of an engineered peptide to activate gut receptors to trigger metabolic effects, Syntis’s technology forms a coating in intestines that has the effect of redirecting nutrients, mimicking an effect of gastric bypass surgery. In other obesity medicine news, Protagonist Therapeutics revealed a drug candidate that puts it in competition with Novo Nordisk and Eli…

Read More